The benefits of aspirin therapy may exceed the potential risk in women with endometrial cancer despite conflicting findings according to a recent review that examined aspirin use and endometrial cancer risk and survival. Researchers reviewed the evidence for the association between endometrial cancer and obesity, the pharmacological differences between regular- and low-dose aspirin, as well as the potential anti-tumor mechanism of aspirin. Among their conclusions:
- Aspirin was shown to have chemo-preventive effects on colorectal cancer.
- Aspirin can suppress platelet activation.
- Aspirin can indirectly inhibit prostaglandin E2, an obesity-related inflammatory marker.
- Aspirin may improve the survival of women with endometrial adenocarcinoma.
- Aspirin use may have a secondary benefit for obesity-related comorbidities including cardiovascular disease in this study population.
Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148:222-232. doi:10.1016/j.ygyno.2017.10.026.